Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Benzinga · 2d ago
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.